- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 612032, 6 pages
NGAL and Metabolomics: The Single Biomarker to Reveal the Metabolome Alterations in Kidney Injury
1Neonatal Intensive Care Unit, Puericulture Institute and Neonatal Section, University of Cagliari, Via Ospedale 119, 09124 Cagliari, Italy
2Department of Laboratory Medicine, University Hospital San Martino, Largo Rosanna Benzi 10, 16132 Genova, Italy
Received 15 December 2012; Accepted 6 March 2013
Academic Editor: Andrew St. John
Copyright © 2013 A. Noto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- R. Frank and R. Hargreaves, “Clinical biomarkers in drug discovery and development,” Nature Reviews Drug Discovery, vol. 2, no. 7, pp. 566–580, 2003.
- M. Mussap, A. Noto, F. Cibecchini, and V. Fanos, “Emerging biomarker in neonatal sepsis,” Drugs of the Future, vol. 37, no. 5, p. 353, 2012.
- N. Paragas, A. Qiu, Q. Zhang et al., “The Ngal reporter mouse detects the response of the kidney to injury in real time,” Nature Medicine, vol. 17, no. 2, pp. 216–222, 2011.
- J. V. Bonventre, V. S. Vaidya, R. Schmouder, P. Feig, and F. Dieterle, “Next-generation biomarkers for detecting kidney toxicity,” Nature Biotechnology, vol. 28, no. 5, pp. 436–440, 2010.
- R. G. Fassett, S. K. Venuthurupalli, G. C. Gobe, J. S. Coombes, M. A. Cooper, and W. E. Hoy, “Biomarkers in chronic kidney disease: a review,” Kidney International, vol. 80, pp. 806–821, 2011.
- P. Devarajan, “Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury,” Biomarkers in Medicine, vol. 4, no. 2, pp. 265–280, 2010.
- L. Kjeldsen, A. H. Johnsen, H. Sengelov, and N. Borregaard, “Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase,” Journal of Biological Chemistry, vol. 268, no. 14, pp. 10425–10432, 1993.
- J. Mishra, M. A. Qing, A. Prada et al., “Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury,” Journal of the American Society of Nephrology, vol. 14, no. 10, pp. 2534–2543, 2003.
- J. B. Cowland and N. Borregaard, “Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans,” Genomics, vol. 45, no. 1, pp. 17–23, 1997.
- D. Portilla, C. Dent, T. Sugaya et al., “Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery,” Kidney International, vol. 73, no. 4, pp. 465–472, 2008.
- T. Kuwabara, K. Mori, M. Mukoyama et al., “Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons,” Kidney International, vol. 75, no. 3, pp. 285–294, 2009.
- S. M. Bagshaw, M. Bennett, M. Haase et al., “Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness,” Intensive Care Medicine, vol. 36, no. 3, pp. 452–461, 2010.
- A. Viau, K. El Karoui, D. Laouari et al., “Lipocalin 2 is essential for chronic kidney disease progression in mice and humans,” Journal of Clinical Investigation, vol. 120, no. 11, pp. 4065–4076, 2010.
- F. C. Grenier, S. Ali, H. Syed et al., “Evaluation of the ARCHITECT urine NGAL assay: assay performance, specimen handling requirements and biological variability,” Clinical Biochemistry, vol. 43, no. 6, pp. 615–620, 2010.
- L. Cai, J. Rubin, W. Han, P. Venge, and S. Xu, “The origin of multiple molecular forms in urine of HNL/NGAL,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 12, pp. 2229–2235, 2010.
- S. Hatipoglu, E. Sevketoglu, A. Gedikbasi, et al., “Urinary MMP-9/NGAL complex in children with acute cystitis,” Pediatric Nephrology, vol. 26, pp. 1263–1268, 2011.
- T. L. Nickolas, C. S. Forster, M. E. Sise, et al., “NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease,” Kidney International, vol. 82, pp. 718–722, 2012.
- S. G. Oliver, M. K. Winson, D. B. Kell, and F. Baganz, “Systematic functional analysis of the yeast genome,” Trends in Biotechnology, vol. 16, no. 9, pp. 373–378, 1998.
- D. S. Wishart, D. Tzur, C. Knox et al., “HMDB: The human metabolome database,” Nucleic Acids Research, vol. 35, no. 1, pp. D521–D526, 2007.
- D. Wishart, “Applications of metabolomics in nutritional science,” Human Metabolome Project, 2008.
- L. Atzori, J. L. Griffin, A. Noto, and V. Fanos, “Metabolomics: a new approach to drug delivery in perinatology,” Current Medicinal Chemistry, vol. 19, pp. 4654–4661, 2012.
- F. C. Marincola, A. Noto, P. Caboni, et al., “A metabolomic study of preterm human and formula milk by high resolution NMR and GC/MS analysis: preliminary results,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 25, pp. 62–67, 2012.
- S. Collino, F. P. Martin, and S. Rezzi, “Clinical Metabolomics paves the way towards future healthcare strategies,” British Journal of Clinical Pharmacology, vol. 75, no. 3, pp. 619–629, 2012.
- J. C. Lindon, J. K. Nicholson, E. Holmes, and J. R. Everett, “Metabonomics: metabolic processes studied by NMR spectroscopy of biofluids,” Concepts in Magnetic Resonance, vol. 12, no. 5, pp. 289–320, 2000.
- D. I. Ellis, W. B. Dunn, J. L. Griffin, J. W. Allwood, and R. Goodacre, “Metabolic fingerprinting as a diagnostic tool,” Pharmacogenomics, vol. 8, no. 9, pp. 1243–1266, 2007.
- U. Christians, J. Albuisson, and J. Klawitter, “The role of metabolomics in the study of kidney diseases and in the development of diagnostic tools,” in Biomarkers in Kidney Disease, C. L. Edelstein, Ed., pp. 39–100, Elsevier Academic Press, San Francisco, Calif, USA, 2011.
- M. Oldiges, S. Lütz, S. Pflug, K. Schroer, N. Stein, and C. Wiendahl, “Metabolomics: current state and evolving methodologies and tools,” Applied Microbiology and Biotechnology, vol. 76, no. 3, pp. 495–511, 2007.
- W. J. Griffiths and Y. Wang, “Mass spectrometry: from proteomics to metabolomics and lipidomics,” Chemical Society Reviews, vol. 38, no. 7, pp. 1882–1896, 2009.
- D. S. Wishart, C. Knox, A. C. Guo et al., “HMDB: a knowledgebase for the human metabolome,” Nucleic Acids Research, vol. 37, no. 1, pp. D603–D610, 2009.
- J. M. Fonville, A. D. Maheir, M. Coen, E. Holmes, J. C. Lindon, and J. K. Nicholson, “Evaluation of full-resolution J-resolved1H NMR projections of biofluids for metabonomics information retrieval and biomarker identification,” Analytical Chemistry, vol. 82, no. 5, pp. 1811–1821, 2010.
- Z. Pan and D. Raftery, “Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics,” Analytical and Bioanalytical Chemistry, vol. 387, no. 2, pp. 525–527, 2007.
- K. K. Pasikanti, P. C. Ho, and E. C. Y. Chan, “Gas chromatography/mass spectrometry in metabolic profiling of biological fluids,” Journal of Chromatography B, vol. 871, no. 2, pp. 202–211, 2008.
- E. Y. Xu, W. H. Schaefer, and Q. Xu, “Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways,” Current Opinion in Drug Discovery and Development, vol. 12, no. 1, pp. 40–52, 2009.
- L. Atzori, R. Antonucci, L. Barberini et al., “1H NMR-based metabolic profiling of urine from children with nephrouropathies,” Frontiers in Bioscience, vol. 2, pp. 725–732, 2010.
- V. Fanos, R. Antonucci, M. Zaffanello, and M. Mussap, “Nenatal drug induced nephrotoxicity: old and next generation biomarkers for early detection and management of neonatal dug-induced nephrotoxicity, with special emphasis on ungal and on metabolomics,” Current Medicinal Chemistry, vol. 19, pp. 4595–4605, 2012.
- L. Atzori, M. Mussap, A. Noto, et al., “Clinical metabolomics and urinary NGAL for the early prediction of chronic kidney disease in healthy adults born ELBW,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 24, supplement 2, pp. 40–43, 2011.